Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma

Launched by METHODIST HEALTH SYSTEM · Sep 1, 2023

Keywords

ClinConnect Summary

This study is an observational project at Methodist Dallas Medical Center looking back at trauma patients who were given a preventive medicine called enoxaparin (a blood thinner) to reduce the chance of clots in the veins. Researchers will compare two ways of giving the drug—weight-based dosing versus a standard fixed dose—based on how much enoxaparin a patient received 48 hours after starting prophylaxis, and they will track how long it takes for any clinically significant bleeding to occur within that 48-hour window.

Who can be included? Adults 18 years and older, weighing at least 50 kg, admitted to the trauma service at Methodist Dallas between Oct 1, 2021 and Mar 31, 2022, who received LMWH for at least 48 hours and were considered high or very high risk for venous thromboembolism (VTE). Exclusions include death, discharge, or hospice within 48 hours of admission; heparin allergy; need for therapeutic (treatment-level) anticoagulation; prisoners; and pregnancy. This is a retrospective study using past records, not a new drug trial, and results are not yet published.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≥18 years of age
• • Admitted to the trauma service between October 1,2021 and March 31, 2022
• • Weight ≥50 kg
• • Received chemical VTE prophylaxis with LMWH for at least 48 hours
• • At "high risk" or "very high risk" of VTE8
• Exclusion Criteria:
• • Death, discharge, or hospice within 48 hours of admission
• • Documented heparin allergy (heparin-induced thrombocytopenia)
• • Indication for therapeutic anticoagulation, either prior to admission or during hospitalization
• • Prisoners
• • \<18 years of age
• • Pregnancy